Related Experiment Video
Updated: Jun 5, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Acquired endocrine resistance in breast cancer: implications for tumour metastasis
Edd Hayes1, Robert I Nicholson, Stephen Hiscox
1Welsh School of Pharmacy, Redwood Building, Cardiff University, Cardiff, UK.
Abstract:
Endocrine therapy is the treatment of choice in hormone receptor-positive breast cancer. However, the effectiveness of these agents is limited by the development of drug resistance, ultimately leading to disease progression and patient mortality. Whilst pre-clinical cell models of acquired endocrine resistance have demonstrated a role for altered growth factor signalling in the development of an endocrine insensitive phenotype, it is becoming apparent that acquisition of endocrine resistance in breast cancer is also accompanied by the development of an adverse cellular phenotype, with resistant cells exhibiting altered adhesive interactions, enhanced migratory and invasive behaviour, and a capacity to induce angiogenic responses in endothelium. Since invasion and metastasis of cancer cells is a major cause of mortality in breast cancer patients, elucidation of molecular mechanisms underlying the adverse cellular features that accompany acquired endocrine resistance and their subsequent targeting may provide a means of limiting the progression of such tumours in vivo.
Insights
Drug resistance limits endocrine therapy for hormone receptor-positive breast cancer. Targeting adverse cellular changes accompanying resistance may limit tumor progression and metastasis.
Area of Science:
- Oncology
- Endocrinology
- Cancer Biology
Background:
- Endocrine therapy is standard for hormone receptor-positive breast cancer.
- Drug resistance limits treatment efficacy, leading to disease progression and mortality.
- Acquired endocrine resistance involves altered cellular phenotypes beyond growth factor signaling.
Purpose of the Study:
- To investigate the molecular mechanisms underlying adverse cellular phenotypes in acquired endocrine resistance.
- To explore the potential of targeting these features to limit breast cancer progression.
Main Methods:
- Utilized pre-clinical cell models of acquired endocrine resistance.
- Analyzed alterations in cellular adhesion, migration, invasion, and angiogenic responses.
Main Results:
- Resistant cells exhibit altered adhesive interactions.
- Enhanced migratory and invasive behaviors were observed in resistant cells.
- Resistant cells demonstrated capacity to induce angiogenic responses in endothelium.
Conclusions:
- Acquired endocrine resistance in breast cancer is associated with an adverse cellular phenotype.
- Understanding and targeting these molecular mechanisms may offer new therapeutic strategies.
- Targeting invasion and metastasis accompanying resistance could limit in vivo tumor progression.
More Related Videos
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mitogens and the Cell Cycle

